Birthweight, childhood body size, and timing of puberty and risks of breast cancer by menopausal status and tumor receptor subtypes
- PMID: 36369105
- PMCID: PMC9652814
- DOI: 10.1186/s13058-022-01578-0
Birthweight, childhood body size, and timing of puberty and risks of breast cancer by menopausal status and tumor receptor subtypes
Abstract
Background: Associations of birthweight, childhood body size and pubertal timing with breast cancer risks by menopausal status and tumor receptor subtypes are inconclusive. Thus, we investigated these associations in a population-based cohort of Danish women.
Methods: We studied 162,419 women born between 1930 and 1996 from the Copenhagen School Health Records Register. The register includes information on birthweight, measured childhood weights and heights at the age of 7-13 years, and computed ages at the onset of the growth spurt (OGS) and at peak height velocity (PHV). The Danish Breast Cancer Cooperative Group database provided information on breast cancer (n = 7510), including estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2) and menopausal status. Hormone replacement therapy use came from the Danish National Prescription Registry. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated by Cox regression.
Results: We found that birthweight was not associated with any breast cancer subtypes. While childhood BMI was not statistically significantly associated with ER+ tumors nor consistently with ER- tumors among pre-menopausal women, consistent inverse associations were found among postmenopausal women. At the age of 7 years, the HRs for postmenopausal ER+ and ER- tumors were 0.90 (95% CI 0.87-0.93) and 0.84 (95% CI 0.79-0.91) per BMI z-score, respectively. Similarly, childhood BMI was inversely associated with pre- and postmenopausal HER2- tumors, but not with HER2+ tumors. Childhood height was positively associated with both pre- and postmenopausal ER+ tumors, but not with ER- tumors. At the age of 7 years, the HRs for postmenopausal ER+ and ER- tumors were 1.09 (95% CI 1.06-1.12) and 1.02 (95% CI 0.96-1.09) per height z-score, respectively. In general, childhood height was positively associated with HER2+ and HER2- tumors among pre- and postmenopausal women. Ages at OGS and PHV were not associated with any breast cancer subtypes.
Conclusions: We showed that a high BMI and short stature in childhood are associated with reduced risks of certain breast cancer subtypes. Thus, childhood body composition may play a role in the development of breast cancer.
Keywords: Body mass index; Breast cancer; Childhood; Height; Menopausal status; Tumor receptor.
© 2022. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Figures

Similar articles
-
Early life body size, pubertal timing, and risks of benign breast disease in a large cohort of Danish female adolescents and women.Eur J Pediatr. 2022 Aug;181(8):3023-3030. doi: 10.1007/s00431-021-04363-x. Epub 2022 Jun 2. Eur J Pediatr. 2022. PMID: 35652986
-
Trajectories of body mass index across the lifecourse and associations with post-menopausal breast cancer by estrogen receptor status.Cancer Epidemiol. 2023 Dec;87:102479. doi: 10.1016/j.canep.2023.102479. Epub 2023 Oct 26. Cancer Epidemiol. 2023. PMID: 37897969
-
Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study.Breast Cancer Res. 2012 May 14;14(3):R76. doi: 10.1186/bcr3186. Breast Cancer Res. 2012. PMID: 22583394 Free PMC article.
-
Birthweight, childhood overweight, height and growth and adult cancer risks: a review of studies using the Copenhagen School Health Records Register.Int J Obes (Lond). 2020 Jul;44(7):1546-1560. doi: 10.1038/s41366-020-0523-9. Epub 2020 Jan 23. Int J Obes (Lond). 2020. PMID: 31974406 Review.
-
Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis.Breast Cancer Res Treat. 2010 Oct;123(3):641-9. doi: 10.1007/s10549-010-1116-4. Epub 2010 Aug 15. Breast Cancer Res Treat. 2010. PMID: 20711809 Review.
Cited by
-
DCIS and LCIS: Are the Risk Factors for Developing In Situ Breast Cancer Different?Cancers (Basel). 2023 Sep 2;15(17):4397. doi: 10.3390/cancers15174397. Cancers (Basel). 2023. PMID: 37686673 Free PMC article.
-
Early life body size and puberty markers as predictors of breast cancer risk later in life: A neural network analysis.PLoS One. 2024 Feb 9;19(2):e0296835. doi: 10.1371/journal.pone.0296835. eCollection 2024. PLoS One. 2024. PMID: 38335218 Free PMC article.
-
Height and breast cancer risk in premenopausal Korean women aged under 40 years of age.Br J Cancer. 2024 Dec;131(12):1913-1918. doi: 10.1038/s41416-024-02846-w. Epub 2024 Oct 7. Br J Cancer. 2024. PMID: 39375531
-
Mitoepigenetics pathways and natural compounds: a dual approach to combatting hepatocellular carcinoma.Med Oncol. 2024 Oct 27;41(12):302. doi: 10.1007/s12032-024-02538-8. Med Oncol. 2024. PMID: 39465473 Review.
References
-
- Larønningen S, Ferlay J, Bray F, Engholm G, Ervik M, Gulbrandsen J, et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 9.0 (01.03.2021). Association of the Nordic Cancer Registries. Cancer Registry of Norway. 2021; Available from: https://nordcan.iarc.fr/. Accessed 4 March 2022.
-
- World Cancer Research Fund International/American Institute for Cancer Research. Continuous Update Project Expert Report 2018: Diet, Nutrition, Physical Activity and Breast Cancer.
-
- Collaborative Group on Hormonal Factors in Breast Cancer Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13:1141–1151. doi: 10.1016/s1470-2045(12)70425-4. - DOI - PMC - PubMed
-
- Lambertini M, Santoro L, Del Mastro L, Nguyen B, Livraghi L, Ugolini D, et al. Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies. Cancer Treat Rev. 2016;49:65–76. doi: 10.1016/j.ctrv.2016.07.006. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous